Severe Malaria Treatment Guideline
For severe malaria in adults and children, intravenous artesunate at 2.4 mg/kg at 0,12, and 24 hours, then daily, is the first-line treatment and should be initiated immediately upon diagnosis. 1
First-Line Therapy: IV Artesunate
The treatment algorithm is straightforward:
- Dosing: 2.4 mg/kg IV at 0,12, and 24 hours, then continue with 2.4 mg/kg daily 1
- Duration: Continue for 7 days if unable to take oral medication OR if parasite density >1% 1
- Transition to oral: If able to take oral medication AND parasite density <1%, switch to a full course of oral artemisinin-based combination therapy (ACT), preferably dihydroartemisinin-piperaquine or artemether-lumefantrine 1
- Pregnancy: Artesunate is now the drug of choice for all three trimesters 2
This recommendation is based on the most recent 2024 guidelines 1 and is reinforced by multiple recent studies demonstrating artesunate's superiority in severe malaria management 3, 2, 4, 5.
Second-Line Alternative: IV Quinine
If artesunate is unavailable, use quinine dihydrochloride:
- Loading dose: 20 mg salt/kg IV over 4 hours 1, 6
- Maintenance: 10 mg/kg IV over 4 hours every 8 hours, starting 8 hours after initiation 1
- Important caveat: Omit loading dose if patient took mefloquine prophylaxis in previous 24 hours or treatment dose within 3 days 6
- Minimum duration: Complete at least 48 hours of IV treatment before switching to oral 1
- Major adverse effects: QT prolongation and hypoglycemia due to insulin release 1
Defining Severe Malaria
Severe malaria requires parasitological confirmation of Plasmodium species PLUS one or more of the following:
Clinical criteria:
- Unarousable coma or multiple convulsions
- Shock or non-cardiogenic pulmonary edema/ARDS
- Acute renal failure (24-hour urine output <400 mL or creatinine >3 mg/dL)
- Jaundice combined with parasite density >100,000/mL
- Bleeding 1
Laboratory criteria:
- Severe anemia (hemoglobin <7 g/dL)
- Acidosis
- Hypoglycemia (glucose <40 mg/dL)
- Hyperparasitemia (>5% for non-immune subjects; >10% for semi-immune) 1
Critical nuance: The parasitemia threshold varies between guidelines (2-5%), but the 2024 European guideline uses >5% for non-immune individuals 1. In practice, parasitemia >4% was the most frequent criterion for ICU admission in the largest European study 1.
Essential Supportive Care
Seizure Management
Follow this algorithmic approach 6:
- Immediate: High-flow oxygen and airway management
- Check glucose: Hypoglycemia may precipitate seizures
- First-line anticonvulsant: Lorazepam 0.1 mg/kg IV/intraosseous
- If seizure continues >10 minutes: Repeat lorazepam 0.1 mg/kg
- If still uncontrolled: Paraldehyde 0.4 mg/kg rectally OR phenytoin 18 mg/kg IV over 20 minutes OR phenobarbital 15-20 mg/kg IV over 10 minutes
- Refractory seizures: Call anesthetist for rapid sequence intubation with thiopental 4 mg/kg 6
Critical warning: Do NOT use prophylactic phenobarbital—it increased mortality in pediatric cerebral malaria trials 6.
Metabolic Monitoring
- Hypoglycemia: Common complication, especially after quinine initiation; monitor glucose closely 7
- Acidosis: Unfavorable prognostic factor requiring correction 7
- Renal function: Acute renal insufficiency may require dialysis 7
Respiratory Support
- Acute pulmonary edema: Frequent in severe imported malaria; mechanical ventilation often required 7
- Intracranial pressure concerns: If signs of raised ICP, elective intubation and ventilation warranted; maintain normal PCO₂ (hyperventilation NOT beneficial) 6
Post-Treatment Monitoring
Critical complication: Post-artesunate delayed hemolysis (PADH) 1
- Monitor hemoglobin for at least 4 weeks after treatment
- Can occur even after successful parasite clearance
Parasitemia monitoring: Check parasite density regularly during treatment to guide transition to oral therapy 4
Common Pitfalls to Avoid
- Delaying treatment: Never wait for parasitological confirmation in suspected severe cases if testing not immediately available 3
- Inadequate IV duration: Must complete minimum 48 hours IV treatment before oral switch 1
- Wrong quinine dosing: Loading dose is 20 mg/kg, not 10 mg/kg; maintenance is 10 mg/kg every 8 hours 1, 6
- Exchange transfusion: Role is questionable in the post-artesunate era; not routinely recommended 7, 2
- Adjunctive therapies: No proven benefit for any adjunctive therapy beyond antimalarials and supportive care 5
Special Populations
Pregnant women:
Children:
- Same artesunate dosing (2.4 mg/kg) 1
- Cerebral malaria more common in older children; severe anemia in younger children 7
Non-falciparum severe malaria: